A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Inclusion Criteria:

• Depending upon study part, a history or status of: 1) a histologically-confirmedhematological malignancy that is expected to express cluster of differentiation (CD)20; 2) relapse after or failure to respond to at least one prior treatmentregimen; and 3) no available treatment options that are expected to prolong survival (e.g., standard chemotherapy or autologous stem cell transplant [ASCT])

• Measurable disease, defined as at least one bi-dimensionally measurable nodallesion, defined as > 1.5 cm in its longest dimension, or at least onebi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longestdimension

• Able to provide a tumor tissue pretreatment biopsy at last relapse or duringscreening from a safely accessible site, per investigator determination, providingthe patient has more than one measurable target lesion

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Life expectancy of >/=12 weeks

• AEs from prior anti-cancer therapy must have resolved to Grade less than or equal to (

• Adequate liver, hematological and renal function

• Negative serologic or polymerase chain reaction (PCR) test results for acute orchronic Hepatitis B virus (HBV) infection

• Negative test results for Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)

• Negative serum pregnancy test within 7 days prior to study treatment in women ofchildbearing potential. Women who are not of childbearing potential who areconsidered to be post-menopausal (at least 12 months of non-therapy amenorrhea) orsurgically sterile (absence of ovaries and/or uterus) are not required to have apregnancy test

Exclusion Criteria:

• Inability to comply with protocol mandated hospitalizations and restrictions

• Participants with chronic lymphocytic leukemia (CLL), Burkitt lymphoma andlymphoplasmacytic lymphoma

• Participants with a known or suspected history of hemophagocytic lymphohistiocytosis (HLH)

• Participants with acute bacterial, viral, or fungal infection at baseline, confirmedby a positive blood culture within 72 hours prior to obinutuzumab infusion or byclinical judgment in the absence of a positive blood culture

• Participants with known active infection, or reactivation of a latent infection,whether bacterial, viral, fungal, mycobacterial, or other pathogens or any majorepisode of infection requiring hospitalization or treatment with IV antibioticswithin 4 weeks of dosing

• Prior treatment with systemic immunotherapeutic agents, including, but not limitedto, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines andmonoclonal antibodies (e.g., anti-cytotoxic T-lymphocyte-associated protein 4 [anti-CTLA4], anti-programmed death 1 [anti-PD1] and anti-programmed death ligand 1 [anti-PDL1]) within 4 weeks or five half-lives of the drug, whichever is shorter,before obinutuzumab infusion on Cycle 1 Day -7

• History of treatment-emergent immune-related AEs associated with priorimmunotherapeutic agents

• Documented refractoriness to an obinutuzumab-containing regimen

• Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment withany other investigational anti-cancer agent, including chimeric antigen receptortherapy (CAR-T) within 4 weeks prior to obinutuzumab infusion

• Prior solid organ transplantation

• Prior allogeneic stem cell transplantation (SCT)

• Autologous SCT within 100 days prior to obinutuzumab infusion

• Participant with history of confirmed progressive multifocal leukoencephalopathy (PML)

• Current or past history of central nervous system (CNS) lymphoma

• Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, orneurodegenerative disease. Participants with a past history of stroke that have notexperienced a stroke or transient ischemic attack in the past 2 years and have noresidual neurologic deficits are allowed

• Evidence of significant, uncontrolled concomitant diseases that could affectcompliance with the protocol or interpretation of results, including diabetesmellitus, history of relevant pulmonary disorders and known autoimmune diseases

• Participants with another invasive malignancy in the last 2 years (with theexception of basal cell carcinoma and tumors deemed by the Investigator to be of lowlikelihood for recurrence)

• Significant or extensive history of cardiovascular disease such as New York HeartAssociation Class III or IV or Objective Class C or D cardiac disease, myocardialinfarction within the last 6 months, unstable arrhythmias, or unstable angina

• Administration of a live, attenuated vaccine within 4 weeks before obinutuzumabinfusion or anticipation that such a live attenuated vaccine will be required duringthe study

• Received systemic immunosuppressive medications (including but not limited tocyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosisfactor agents) within two weeks prior to obinutuzumab infusion. Treatment withcorticosteroid

• Any other diseases, metabolic dysfunction, physical examination finding, or clinicallaboratory finding giving reasonable suspicion of a disease or condition that wouldcontraindicate the use of an investigational drug

• History of autoimmune disease, including but not limited to myocarditis,pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus,erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosisassociated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren'ssyndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, orglomerulonephritis. Participants with a remote history of, or well controlledautoimmune disease, may be eligible to enroll after consultation with the MedicalMonitor

• In Part III diffuse large B-cell lymphoma (DLBCL) dexamethasone cohort, participantswith a history of hypersensitivity to dexamethasone or systemic corticosteroids willbe excluded